Amifostine for Head and Neck Irradiation in Lymphoma

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is determine the effects (good and bad) amifostine has on radiation-induced side effects of lymphoma treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Collaborators: Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; MedImmune LLC
• Treatments: Amifostine

Criteria

Inclusion Criteria:

• Patients must be 35 years or older

• Histologically confirmed Hodgkin's disease or non-Hodgkin's lymphoma receiving radiation therapy to the head and neck area.

• Involvement of one or more of the following sites: cervical node, supraclavicular node, pre-auricular node, submental node, any salivary glands, any parts of the oral cavity, or any parts of the oropharynx.

Exclusion Criteria:

• Prior history of head and neck malignancies

• Prior radiation therapy to the head and neck region

• Patients with stage I Hodgkin's disease receiving radiation therapy alone

• Pregnant or lactating women

• Myocardial infarction within the 6 months of enrollment

• Clinically evident pulmonary insufficiency, except for patients with exertional dyspnea related to chest tumor itself.